
|Articles|June 1, 2003
Bucking the One-Time Trendsetter
San Francisco - According to an analysis of data from more than 700 patients, a new nonsteroid treatment for atopic dermatitis is a safe, effective, and cost-effective alternative to conventional therapy for the chronic, relapsing inflammatory skin disease that primarily affects infants and children.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Phase 2 Nemolizumab Trial Opens for CPUO
4
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
5


















